<SEC-DOCUMENT>0001558370-19-010800.txt : 20191112
<SEC-HEADER>0001558370-19-010800.hdr.sgml : 20191112
<ACCEPTANCE-DATETIME>20191112160559
ACCESSION NUMBER:		0001558370-19-010800
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20191112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191112
DATE AS OF CHANGE:		20191112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911663741
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34475
		FILM NUMBER:		191209304

	BUSINESS ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
		BUSINESS PHONE:		206-676-5000

	MAIL ADDRESS:	
		STREET 1:		201 ELLIOTT AVENUE WEST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>omer-20191112x8k3397499.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.4.7193.41938 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/12/2019 9:05:36 PM -->
      <!-- iXBRL Library version: 1.0.7193.41955 -->
      <!-- iXBRL Service Job ID: 72a8c0e1-453f-4a42-9462-07ea25d3a57e -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:omer="http://www.omeros.com/20191112" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:EntityCentralIndexKey" id="Hidden_Wa_jfEWeEU24VPQtU1k4Dw">0001285819</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:AmendmentFlag" id="Hidden_wKz9Oslh906kWDCXegOtow">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="omer-20191112.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001285819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-12</xbrli:startDate><xbrli:endDate>2019-11-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:18pt;font-weight:bold;text-align:center;text-indent:0pt;margin:0pt;">FORM&#160;<ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:DocumentType" id="Narr__vxu1RrgO0K0z0LF1Y9xQA">8-K</ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_djnq3ODF5US4OaPFD-K3KA"><b style="font-weight:bold;">November 12, 2019</b></ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:24pt;font-weight:bold;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:EntityRegistrantName" id="Narr_huuTwTDauEy81T9CGGqszA">OMEROS CORPORATION</ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as Specified in Its Charter)</b></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_439b5711_d9b7_412e_9fb8_26d33a59c6a2"></a><a id="Tc_Wds1bXNM1EiLP5k1yNhW4Q_1_0"></a><a id="Tc_XfYNYjAS-U-s-EkfGH-bTA_1_1"></a><a id="Tc_j_pa-kGRJ0edvY1ZzzpGcA_1_2"></a><a id="Tc_8Hw0JnbpoE-w2U_jtL-fuQ_3_0"></a><a id="Tc_XMjDwg77dEKy-zUxDuKd1g_4_0"></a><a id="Tc_Fz26EU8Xwk2VL8FmlCj7Mg_4_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_9cACTKAuF0S4LkpJ7ycMnw_0_0"><b style="font-weight:bold;">Washington</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:EntityFileNumber" id="Tc_1bftqEFa10-WJ5spGHfOOg_0_1"><b style="font-weight:bold;">001-34475</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:EntityTaxIdentificationNumber" id="Tc_XsvEozzFyU2H3zG6uCZ4xA_0_2"><b style="font-weight:bold;">91-1663741</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or Other Jurisdiction</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Incorporation)</b></p></td><td style="vertical-align:top;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:6pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:6pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:6pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:EntityAddressAddressLine1" id="Narr_YkGsLX_Dqki7KTv1hJd-xA"><b style="font-weight:bold;">201 Elliott Avenue West</b></ix:nonNumeric><br /><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:EntityAddressCityOrTown" id="Narr_HeUgZojYnUuLqGNxuncoGw"><b style="font-weight:bold;">Seattle</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:EntityAddressStateOrProvince" id="Narr_zA4JWxdjN0u3fcMkuhSgNw"><b style="font-weight:bold;">WA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.29%;margin:0pt;padding:0pt 1pt 0pt 2pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:EntityAddressPostalZipCode" id="Tc_HfN4s6XJCk62gYkRmQrGmg_3_2"><b style="font-weight:bold;">98119</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of Principal Executive Offices)</b></p></td><td style="vertical-align:bottom;width:33.29%;margin:0pt;padding:0pt 1pt 0pt 2pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s Telephone Number, Including Area Code: (</b><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:CityAreaCode" id="Narr_6Z7uulVm906IIzFfRi_gng"><b style="font-weight:bold;">206</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:LocalPhoneNumber" id="Narr_qniYHwWuOkKcKwj-_6dHGA"><b style="font-weight:bold;">676-5000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Former Name or Former Address, if Changed Since Last Report)</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_7Bhx_O2rAkaLYWVyNgcYGg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_soFLsgWsRkSc49NqJjYwvw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_6J_0O4d8ZUCp_OoqlDuqUg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_Fnxx0O94QECoWVCASNdKKA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Securities Registered Pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_fc824eb1_f8ea_4b0e_83a7_c681efbb8280"></a><a id="Tc_dgnEpYIdPkqBP7oRpFQq-w_0_0"></a><a id="Tc_KCDDkDdTokqM7u2OmdtTwg_0_1"></a><a id="Tc_e2Yec-vHWkm40pT-TmTCBQ_0_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:38.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:23.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:37.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:bottom;width:38.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:Security12bTitle" id="Tc_PagvLSZpyU-jYkDUk10Wmw_1_0">Common stock, $0.01 par value per share</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:23.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" name="dei:TradingSymbol" id="Tc_1LeJB3Ase02AgB0S7X1QoQ_1_1">OMER</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:37.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_Lk7_6Kb8b0yu1ltm_oQE2w_1_2">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).<span style="display:inline-block;width:0.75pt;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_h48fTZC4wEGclUnXUCes0w"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.02 Results of Operations and Financial Condition.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 12, 2019, Omeros Corporation issued a press release announcing financial results for the three&#160;and nine months ended September 30, 2019.&#160;A copy of such press release is furnished herewith as Exhibit&#160;99.1 and is incorporated herein by reference.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information in this Current Report on Form&#160;8-K, including the exhibit hereto, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section&#160;or Sections 11 and 12(a)(2)&#160;of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the United States Securities and Exchange Commission made by Omeros Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p><p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01 Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits.</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b> <br /><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:87.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:9.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="ex-99d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release, dated November 12, 2019, pertaining to Omeros Corporation&#8217;s financial results for the three and nine months ended September 30, 2019.</span></a></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OMEROS CORPORATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Date: November 12, 2019</p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">/s/ Gregory A. Demopulos</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Gregory A. Demopulos, M.D.</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">President, Chief Executive Officer and</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chairman of the Board of Directors</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.4.0.81-->
<!--Created on: 11/12/2019 2:05:27 PM-->
<html>
	<head>
		<title>
			omer_EX99_1
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="ex-99d1g001.jpg" style="width: 1.5in; height: 1.010417in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Omeros Corporation Reports Third Quarter 2019 Financial Results</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">&#x2013;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;"> Conference Call Today at 4:30 p.m. ET </font><font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">&#x2013;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">SEATTLE, WA &#x2013; November 12, 2019 &#x2013; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2019.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Third Quarter 2019 Financial Highlights</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;color:#000000;">&#xF0B7;<font style="display:inline;font-family:Symbol;color:#000000;;font-size: 11pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 11.7pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">3Q 2019 revenues were $29.9 million, another quarter of record sales of OMIDRIA</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE; &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">(phenylephrine and ketorolac intraocular solution) 1%/0.3%. This compares to $26.8 million in 2Q 2019, an increase of $3.1 million, or 12 percent.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;<a name="_Hlk23496107"></a></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Net loss in 3Q 2019 was $16.5 million, or $0.33 per share. This compares to a net loss $14.5 million, or $0.29 per share, in 2Q 2019.&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">Net loss in each period included non-cash expenses of $6.3 million, or $0.13 per share.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">At September 30, 2019, Omeros had cash, cash equivalents and short-term investments available for operations of $27.3 million, a decrease of $4.5 million from June 30, 2019. Accounts receivable at September 30, 2019 were $29.9 million. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">Omeros has a $50-million revolving line of credit facility with Silicon Valley Bank. The line of credit provides for borrowing availability of up to the lesser of $50 million and 85 percent of eligible accounts receivable, subject to applicable r</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">eserves. As of September 30, 2019 there were no borrowings outstanding.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Recent Business Highlights</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">S</font><font style="display:inline;color:#000000;font-size:11pt;">ubmitted to the U.S. Food and Drug Administration (FDA) the nonclinical sections of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Received from the Pediatric Committee of the&nbsp;European Medicines Agency&nbsp;(EMA) a positive opinion on the pediatric investigation plan for narsoplimab in the treatment of HSCT-TMA. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-size:11pt;">Reported positive results from a Phase 1 study of the lead compound in Omeros&#x2019; OMS527 program focused on development of phosphodiesterase 7 (PDE7) inhibitors for the treatment of addiction and compulsive disorders. In the double blind, randomized Phase 1 study, the study drug, referred to as OMS182399, met the primary endpoints of safety and tolerability and showed a favorable pharmacokinetic profile supporting once-daily dosing.&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-size:11pt;">P</font><font style="display:inline;color:#000000;font-size:11pt;">resented data on a series of d</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">iscoveries showing that GPR174, a member of the family of G protein-coupled receptors (GPCRs), controls a new axis in cancer immunity. In addition to demonstrating the potential of GPR174 as a standalone anti-cancer agent, these data show that the combined inhibition of both GPR174 and the adenosine pathway synergistically enhances T-cell response. This synergistically enhanced T-cell response could significantly improve the effectiveness of checkpoint inhibitors and other anti-cancer drugs.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Scientists from Omeros along with academic collaborators from the University of Toronto were awarded the Prix Galien Canada Research Award for 2019 in recognition of their development of the drug discovery technologies underlying Omeros&#x2019; GPCR platform. The Prix Galien is the most prestigious award in the field of Canadian pharmaceutical research and innovation and recognizes the research team judged to have made the most significant contribution.</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">&#x201C;Initiating submission of our rolling BLA for narsoplimab in stem </font><font style="display:inline;color:#000000;font-size:11pt;">cell transplant-associated TMA is a significant milestone on our path to becoming a multi-product commercial biopharmaceutical company and, more importantly, is a major advance in our mission to treat these patients,&#x201D; said Gregory A. Demopulos, M.D., Omeros&#x2019; chairman and chief executive officer. &#x201C;We are on track to complete submission of our BLA in the first half of 2020 and preparations for the anticipated commercial launch of narsoplimab are also progressing. We continue to grow utilization of OMIDRIA, delivering record quarterly sales in Q3 and projecting a new all-time high in the fourth quarter. The remainder of our pipeline assets are also progressing &#x2013; OMS527 has successfully completed its Phase 1 trial in our addiction program, our MASP-3 inhibitor OMS906 is on track to enter the clinic in the first half of next year, and our GPR174 immuno-oncology program continues to generate exciting new </font><font style="display:inline;font-style:italic;color:#000000;font-size:11pt;">in vivo</font><font style="display:inline;color:#000000;font-size:11pt;"> data, which will be presented for the first time later this month at the AACR conference in Boston.&#x201D;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Other Business Updates and Developments</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Recent developments regarding OMIDRIA include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">The new product-specific permanent J-code for OMIDRIA became effective October 1, 2019. J-codes standardize the submission and payment of insurance claims across Medicare, Medicare Advantage, Medicaid and commercial insurance plans. The J-code has been broadly uploaded to Medicare and commercial payer systems nationwide and is expected to expand reimbursement to commercial, Medicare Advantage and Medicaid insurers that would not reimburse for OMIDRIA under the prior C-code and to enable access to the increasing number of cataract procedures performed in the physician office setting.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">In October, a manuscript authored by Keith Walter, M.D. of Wake Forest University, was accepted for publication in the peer-reviewed </font><font style="display:inline;font-style:italic;color:#000000;font-size:11pt;">Journal of Cataract and Refractive Surgery</font><font style="display:inline;color:#000000;font-size:11pt;">. Dr. Walter&#x2019;s study consisted of a retrospective analysis of 504 eyes (357 patients) on whom he had performed cataract surgery using OMIDRIA plus only a topical non-steroidal anti-inflammatory drug (NSAID), assessing the incidence of CME. The control group consisted of a collection of single and meta-analytic studies published in the peer-reviewed literature in which steroids, with and without topical NSAIDs, were used in cataract surgery in the absence of OMIDRIA. Of the 504 eyes treated with OMIDRIA, only two developed postoperative CME, an incidence of 0.39 percent, which is 3- to 12-fold lower than the CME rates in the published peer-reviewed studies.&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-size:11pt;">On November 1, 2019, the Centers for Medicare and Medicaid Services (CMS) issued the 2020 final rule for its outpatient prospective payment system (OPPS). CMS had described criteria that must be met in order for products to be eligible for separate payment under legislation requiring CMS to review its OPPS payments with a goal of ensuring that there are not financial incentives to use opioids for pain management instead of non-opioid alternatives. Although Omeros submitted to CMS data for OMIDRIA that meet the criteria, CMS declined in its 2020 final rule to grant separate payment for OMIDRIA beyond the expiration of its current pass through status on September 30, 2020. CMS indicated it would continue to analyze evidence and monitor utilization of OMIDRIA and Omeros intends to continue its administrative and legislative efforts to secure ongoing separate payment for OMIDRIA. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-size:11pt;">On November 4, 2019 the results of an independent investigator study of the effect of OMIDRIA use on the utilization of fentanyl, an opioid, in cataract surgery were published in the peer-reviewed journal </font><font style="display:inline;font-style:italic;font-size:11pt;">Clinical Ophthalmology</font><font style="display:inline;font-size:11pt;">. The article,&nbsp;</font><font style="display:inline;font-style:italic;font-size:11pt;">The Effect of Phenylephrine/Ketorolac Intracameral Solution 1%/0.3% on Pain and Opioid Use During Cataract Surgery</font><font style="display:inline;font-size:11pt;">, is authored by the study investigator&nbsp;Eric D. Donnenfeld, M.D., Clinical Professor of Ophthalmology at&nbsp;New York University&nbsp;and recent past president of the&nbsp;American Society of Cataract and Refractive Surgery.&nbsp;The prospective, controlled study showed that use of OMIDRIA in cataract surgery had a direct, clinically meaningful and statistically significant effect on reduction in fentanyl use (77% reduction, p = 0.006) while reducing visual analog scale (VAS) pain scores by approximately 50 percent (p &lt; 0.0001).</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Recent developments regarding narsoplimab, Omeros&#x2019; lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) in Phase 3 clinical programs for the treatment of HSCT-TMA, Immunoglobulin A (IgA) nephropathy, and atypical hemolytic uremic syndrome (aHUS), include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">In October, Omeros submitted to FDA the nonclinical (i.e., pharmacology, pharmacokinetics and toxicology) data, study reports, overview and summary sections of its rolling BLA for narsoplimab to treat HSCT-TMA. Once all clinical data collection, dataset compilation and data analyses are complete, the clinical sections of the BLA </font></p></td></tr></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top"><p style="margin:0pt 0pt 6pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;;"><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">will be submitted, followed by the quality (i.e., chemistry, manufacturing and controls) sections. Submission of the clinical and quality sections remains on track for scheduled completion in the first half of next year.&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">The Pediatric Committee of the EMA issued a positive opinion for Omeros&#x2019; pediatric investigation plan (PIP) for narsoplimab in the treatment of HSCT-TMA. Agreement with the pediatric committee on a PIP outlining a development program for the investigational product in the pediatric population is a prerequisite to EMA&#x2019;s acceptance of a Marketing Authorization Application (MAA) for the product. Omeros received a deferral for completion of its pediatric plan until after EMA approval of the MAA planned for submission to EMA for narsoplimab in the treatment of HSCT-TMA. With successful completion of the PIP, narsoplimab would be eligible for up to an additional two years of marketing exclusivity.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Omeros&#x2019;&nbsp;Phase 3 trial evaluating narsoplimab for IgA nephropathy, referred to as ARTEMIS-IGAN, continues enrollment at an increasing number of sites in the U.S. and internationally. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">A manuscript prepared by Omeros&#x2019; Academic Leadership Committee detailing the clinical data from the Phase 2 IgA nephropathy program is expected to be published in a peer-reviewed journal. In addition, a report detailing the response to narsoplimab treatment by a patient with IgA vasculitis-associated nephritis and rapidly progressive glomerulonephritis has been submitted for publication. </font></p></td></tr></table></div>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Updates regarding Omeros&#x2019; other development programs and platforms include the following:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">IND-enabling toxicology studies have begun for OMS906, Omeros&#x2019; MASP-3 inhibitor, in advance of clinical entry slated for the first half of next year. Targeting subcutaneous dosing of twice-monthly or less frequently, this program is initially targeting paroxysmal nocturnal hemoglobinuria.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Omeros continues life-cycle management within its MASP-2 program. These efforts are directed to development of a longer-acting second-generation antibody against MASP-2 as well as an orally available small-molecule inhibitor of MASP-2, both targeted for clinical entry in 2021.</font></p></td></tr></table></div>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;color:#000000;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:0pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">A presentation entitled &#x201C;Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T cell responses&#x201D; will be made at the American Association for Cancer Research conference on Tumor Immunology and Immunotherapy to be held in Boston, November 17-20, 2019. It will include additional animal data that validate GPR174 inhibition for cancer immunotherapy. The company&#x2019;s GPR174 program has also been selected for participation in the 2019 Immuno-Oncology Congress of the European Society for Medical Oncology to be held in Geneva, December 11-14, 2019.</font></p></td></tr></table></div>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;">Financial Results</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">3Q 2019 revenues,</font><font style="display:inline;">&nbsp;</font><font style="display:inline;color:#000000;font-size:11pt;">all related to sales of OMIDRIA,</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;font-size:11pt;">were</font><font style="display:inline;">&nbsp;</font><font style="display:inline;color:#000000;font-size:11pt;">$29.9 million, a</font><font style="display:inline;">&nbsp;</font><font style="display:inline;color:#000000;font-size:11pt;">new</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;font-size:11pt;">record high.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;color:#000000;font-size:11pt;">On a sequential quarter-over-quarter basis, OMIDRIA revenues increased by $3.1 million, or 12 percent, from the $26.8 million achieved in 2Q 2019.&nbsp;The increase is due to a growing number of purchasing accounts as well as deeper penetration within accounts across hospitals, ASCs, Veterans Administration and other government payers.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Gross-to-net deductions in 3Q 2019 remained consistent with those in 2Q 2019 at 28 percent&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">3Q 2019 costs and expenses were $41.0 million compared to $36.1 million for Q2 2019. The increase reflected incremental narsoplimab manufacturing costs associated with the commencement of full-scale drug substance manufacturing in 3Q 2019 together with increased manufacturing scale-up costs in our OMS906 program in advance of planned clinical entry next year. Selling, general and administrative expenses were $16.9 million for both 2Q and 3Q 2019.&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">For 3Q 2019, Omeros reported a net loss of $16.5 million, or $0.33 per share, compared to a net loss of $14.5 million, or $0.29 per share, in 2Q 2019. Net loss in both 2Q 2019 and 3Q 2019 included non-cash expenses of $6.3 million ($0.13 per share).</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">As of September 30, 2019, Omeros had $27.3 million of cash, cash equivalents and short-term investments available for operations,&nbsp;a decrease of $4.5 million from June 30, 2019. Accounts receivable at&nbsp;September 30, 2019 were $29.9 million.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 6pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;color:#000000;font-size:11pt;">Omeros has a $50-million revolving line of credit facility with Silicon Valley Bank. The line of credit provides for borrowing availability of up to&nbsp;the lesser of $50 million and 85 percent of eligible accounts receivable, subject to applicable reserves. As of September 30, 2019, there were no borrowings outstanding.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 5pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Conference Call Details</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Omeros&#x2019; management will host a conference call to discuss the financial results and to provide an update on business activities. The call will be held today at 1:30 p.m. Pacific Time; 4:30 p.m. Eastern Time. To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 9699377. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 9699377.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">To access the live or subsequently archived webcast of the conference call on the internet, go to the company&#x2019;s website at </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">www.omeros.com</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and select &#x201C;Events&#x201D; under the Investors section of the website. To access the live webcast, please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">About&nbsp;Omeros Corporation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Omeros&nbsp;is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial drug </font><font style="display:inline;font-size:11pt;">OMIDRIA</font><font style="display:inline;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-size:11pt;"> (phenylephrine and ketorolac intraocular solution) 1%/0.3%</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, Omeros&nbsp;has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros&#x2019; proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:11pt;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the &#x201C;safe harbor&#x201D; created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;could,&#x201D; &#x201C;estimate,&#x201D; &#x201C;expect,&#x201D; &#x201C;goal,&#x201D; &#x201C;intend,&#x201D; &#x201C;likely,&#x201D; &#x201C;look forward to,&#x201D; &#x201C;may,&#x201D; &#x201C;objective,&#x201D; &#x201C;plan,&#x201D; &#x201C;potential,&#x201D; &#x201C;predict,&#x201D; &#x201C;project,&#x201D; &#x201C;should,&#x201D; &#x201C;slate,&#x201D; &#x201C;target,&#x201D; &#x201C;will,&#x201D; &#x201C;would&#x201D; and similar expressions and variations thereof. Forward-looking statements are based on management&#x2019;s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros&#x2019; actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with product commercialization and commercial operations, unproven preclinical and clinical development activities, regulatory oversight, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading &#x201C;Risk Factors&#x201D; in the company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2019, as supplemented from time to time by the company&#x2019;s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Contact</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Jennifer Cook Williams</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Cook Williams Communications, Inc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Investor and Media Relations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">360.668.3701</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">jennifer@cwcomm.org</font><font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">OMEROS CORPORATION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(In thousands, except share and per share data)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 92.00%;">
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:30.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Three&nbsp;Months&nbsp;Ended<br>September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:30.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Nine&nbsp;Months&nbsp;Ended<br>September&nbsp;30,</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;color:#000000;font-size:11pt;"> &nbsp;&nbsp; </font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;height:13.60pt">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;background-color: #CCEEFF;height:13.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 20.9pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Product sales, net</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29,856
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,608
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78,389
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,852
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Costs and expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 20.9pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Cost of product sales</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>278
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>464
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;padding-right:1.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>355
				</td>
				<td valign="bottom" style="width:00.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 20.9pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,746
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,862
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>69,108
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;padding-right:1.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64,414
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 20.9pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Selling, general and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,933
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,152
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,493
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,830
				</td>
				<td valign="bottom" style="width:00.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 34.55pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Total costs and expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,957
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,050
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>118,065
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101,599
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,101)
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(35,442)
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39,676)
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(93,747)
				</td>
				<td valign="bottom" style="width:00.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Interest expense</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,715)
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,602)
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,846)
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,104)
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Other income</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>353
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>572
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,628
				</td>
				<td valign="bottom" style="width:00.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,463)
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39,472)
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55,261)
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(103,223)
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,463)
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39,472)
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55,261)
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(103,223)
				</td>
				<td valign="bottom" style="width:00.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Basic and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.33)
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.81)
				</td>
				<td valign="bottom" style="width:02.20%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.12)
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.13)
				</td>
				<td valign="bottom" style="width:00.46%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.38%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Weighted-average shares used to compute basic</font></p>
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49,373,156
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,647,416
				</td>
				<td valign="bottom" style="width:02.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49,157,055
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.56%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,437,870
				</td>
				<td valign="bottom" style="width:00.46%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">OMEROS CORPORATION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">UNAUDITED CONSOLIDATED BALANCE SHEET DATA</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(In thousands)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;padding:0.8pt 0.8pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.38%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:11pt;"> &nbsp;&nbsp; </font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,<br>2019</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:11pt;"> &nbsp;&nbsp; </font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,<br>2018</font></p>
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Cash, cash equivalents and short-term investments</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,342
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">$</font></p>
				</td>
				<td valign="middle" style="width:08.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,498
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Working capital</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,046
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,511
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Restricted investments</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,154
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,154
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Total assets</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91,263
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,936
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Total current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,753
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,356
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,709
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,467
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Convertible Senior Notes</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>155,771
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148,981
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Accumulated deficit</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(705,386)
				</td>
				<td valign="bottom" style="width:02.04%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(650,125)
				</td>
				<td valign="bottom" style="width:00.38%;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:76.90%;background-color: #CCEEFF;padding:0.8pt 0.8pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;color:#000000;font-size:11pt;">Total shareholders&#x2019; deficit</font></p>
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(139,915)
				</td>
				<td valign="bottom" style="width:02.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:08.50%;background-color: #CCEEFF;color:#000000;font-family:Times New Roman,Times,serif;font-size:11pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(100,156)
				</td>
				<td valign="bottom" style="width:00.38%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH K7]Y'I]A-=R_<B4MCU]!^)KG?!NLRWZW5O<ONF#F92?[K'D?@
M?YU4\=ZEDP:9&W_367'_ (Z/YG\JQ=,O?[!GLI_XYR))QZ0G@#\>6_!:\7$8
MUQQ:2?NQW^?]?F>O0P?-A6VO>EM\CU"BD!#*&4@@C((I:]H\@**** "BBB@
MHHHH **** "BBB@ HHHH *9-,EO!)-(=L<:EF/H!3ZYGQM>-%I*6D9P]R^T_
M[HY/]*QQ%54J4JG8UH4G5J*'<Y.TCE\1^)=TF0)W\Q_]E!V_( 5H>.%L_P"T
M(! P\](]DJJ. /X?QZ_I5_0(5T7P]>:PR@NZ?NQCL.!^9KF=.T^YUW5?*+G?
M)N>21N<>I/XU\[.+C15.UYU'?_+[SWHR4JSG>T(*W^?W#5N]7U%([.*XN955
M0B1HQ P!QT_K7IVG74$MI#$EQ%)*D85U5P2"!SG\:X#PQ>OI'B(03_(LK&"4
M'LV>/UX_&I=2\*:M93RWUN5E&]I 8&(=<G/3_"M<%5J4H.K%.3V:[6,\72A5
MFJ<FHK=>=ST>BN=\)Z[)JUF\-R0;F#&6_OJ>A^OK715[U&M&M!5(;,\2K2E2
MFX2W04445J9A1110 4444 %%%% !1110 5Y_?!_$WBQX(LF"+]UO'\*#[S?4
MG(%=EK%Q);:9*8!NN)/W<2^KMP/\?PJ+1='ATBT"* 9F4>;)_>-<6)I.O.-+
M[*U?Z([,/45"+J=7HOU9%KUH/^$8N+>%2%CC&U1Z*0?Z5B>!XU%U?L1\V$Q]
M"2?\*[)@&4JP!!&"#WKF8+-_#^K/-Y;O8RC!D49V<Y&1_6HKT>7$0K=%IZ;_
M .95&KS4)TNKU*?B'PG=WVK-=V!B"R*"X9MI#CN./I766?VC[%"+L*+@(!)M
M.1GN:DCECF0/$ZNIZ%3D5C^)=:FT2SAFABCD:2380Y.!P3V^E:*G1PW/76SW
M(=2KB.6CVV*VEV*V_C/59(5VP^4FX#H';D_RS^-=)7G=KXSO8=RQ6,#/(Q=V
MRV6;U_SZ5T&D:SK.H2CSK".*+UVMD_GQ6&$Q="W)"^K;V?5FV*PM;XYVT26_
M8Z2BD&<<]:6O3/."BBB@ HHHH **** "BBB@!CQ)(\;LN6C.5SV.,9I]%%%@
MN8/B#P^=4C,]K,\-XHXPY"O['_&N'.E:^I(^RW^0<'!8_P!:]6HKS\3EU.M+
MGNT_([L/CZE&/+:Z\SB?!EAJ%IJEP]W;7$2-#@&0$ G<*ZC4])M-7A2*[5F5
M&WC:Q'.,5>HK>CA84J7LGJO,QK8F=2K[5:/R,.+PEH\,BR1P2!@<_P"N;_&M
MJ.-(D"1J%4=A3J*UIT:=/X(I&<ZLZGQML****T,PHHHH **** /+_%7BO5=8
M\9P^#_#MT;3Y]ES=H/F!QE@#V"C\2>*V_$?AC4(/#,+Z+K>IQZAID3-&SSEO
MM'\1#_WCQQZ=*X+X4/\ VE\1-0OY>9&@FFR?5Y%_Q->Y=:ZJS]E)1CT.+#_O
MHRG+K^!QOP[\9MXMTB0705=0M2%FVC <'[K@=LX.1ZBN9^*WB/6- \0:2VF7
M\T"^27:)6^1R&_B'0UB?"Z4V/Q*OK*,_NY$GBQ_NOD?RKH/B3I7]M>+;"Q"[
MI6TNY>(#^^OS+^HQ^-:<D85_(S]I.IAM];V/1M(U&/5]'L]1B^Y<PK*!Z9&<
M?ATKR;6O&6IW?Q8MM/LM0GAT^&]AM6BC?"R88;\^O)(^@K2^&WBF.U^'.I&=
MLMI =P#W1@64?]];A7&6FF/IWC'P>T^3=7I@O)R>NZ29C_+%%*DHSE?Y"K5I
M3IP<>MKGO&M:M;Z'HUUJ=T3Y-O&7('5CV ]R<#\:\Z\*6^L?$,W6LZSJE[:Z
M>LICM[.RF,2Y'7)') R!GJ3FKOQGNFA\(VUNIP)[M0WN%5C_ # J3P9XCT+P
MSX"T2+4[^*UDN(Y)5# G=\YR>![BLX1<:7-%:MFTYJ5?DD]$KG6Z)HLNB^?'
M_:E[>V[E3$EV_F-%C.0'ZD'CKTQ7G>L:AJMU\9!H2ZQJ%MI\VP&.WFV;?W.[
MCTY%>CZ-XATKQ#%++I5XEU'$VQV52,'&<<@5YEJ!"?M!6[,0% 4DGL/(-*C?
MFES;V88BRA#E>ET/UC6M=^'OC*SAN-7N=3T>[ ;;=$,ZKG#<^HX/H:]-UO5[
M?0M%NM4NLF*WCW$#JQZ #W)P/QKR_P 31CXC^.K"ST<^?IU@H%U>)_JUW-EL
M'OPN!ZG/89K8^,]RT/A*UMU.%GNU#>X56./SQ^57*"G*$7N]R8U'"-22V6Q'
MX$DUSQE?R>)-5U*XALX)BMK8V[[(B0.=P_B SCGJ<^E5/$>IZS\./$EM=+?W
M6H:'?,Q>WN7WM&<Y8*3TX.1^1Z9KJ_AI"L/P]TD*/OH[GW)=C6-\9H5?P;!*
M1\T=XFT_56!I*2=;E:TV"46L/SI^]N==K'B&UTKPO/KH_?6Z0"6,*?\ 6;L;
M1^)(KB_"-AJOC>V'B#7M6NTMWE/V:RLY3#&H4XR=O)Y!_+K3=$L)_%/P073X
MSFX$;)%D]3'(2H_0"LCX7^-(M)SX8UC-OB9A;R2#&QR>8V].<X]SCTH5/EA+
MEW3_  "57FJ0Y_A:_$],O-#FNKR2=-5O( ^/DC; &!16Q17-SR.MTXL\-^'\
M9\/_ !9N]*F^0D3VZYXS@AU_,+G\:]OFF2W@DFE;;'&I=B>P R:XKQGX'?5M
M0M]?TBZ2SUBT(8.X.R0+R-V.XZ9P<C@UAW/B#Q'XUMY?#EM#8:?+(/+N[@3.
MP9?X@@V\9]S73./MFIKYG)3E]73IOY&'\(;234?&6H:N5/E11.2?]N1L@?D&
MKNM7_P"2N^'?^O&XK<\+^&;/PKHR:?:9<YWRS,,-*_<GT]AV%4[_ $>XG^(6
MD:LKQ"WMK66)U).\ENF!C&/QI3J*=1M;6?Y%4Z+ITHQ>]T_Q/,+318[3XD:S
MX2GWI8ZJ&5=G\(R)D/X8*_B:U/&P6/XQ>&D0!506P '0#S6KT67PY!+XSM_$
M1V^9%:-;[<<Y+9#?D6'XURWBKPIJ&I_$72=8@EMEM[7R-ZR.P<[9"3@!2.A]
M:N%52DO3\3*=%P@TOYOP'?&.Q>Y\&QW**3]DND=\=E(*Y_,BM#X926]]\/\
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MV.G^'VG2:7X%TNWE4K*T9E<'J"Y+?R(KD?B_X6LGTH^(H$6*[B=4GP,"92<
MG_:!QSZ?A7JG0<5YE<V^J?$Z9K:66'3M#M+DK+'&Q>:9E)'4@ #KC^M9TI2]
MI[3IU-:\(^R5+=]#J? -]<ZCX&TJYNV9YC$5+MU8*Q4$_@!16[9VD%A90V=K
7&(X($$<:#L ,"BL)-.3:.F"<8I,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>omer-20191112.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.7193.41938 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2019 9:05:36 PM-->
<!--Modified on: 11/12/2019 9:05:36 PM-->
<xsd:schema targetNamespace="http://www.omeros.com/20191112" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:omer="http://www.omeros.com/20191112">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.omeros.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="omer-20191112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="omer-20191112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="omer_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>omer-20191112_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.7193.41938 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2019 9:05:36 PM-->
<!--Modified on: 11/12/2019 9:05:36 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="omer-20191112.xsd#omer_DocumentAndEntityInformationAbstract" xlink:label="omer_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="omer_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="omer_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>omer-20191112_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.7193.41938 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2019 9:05:36 PM-->
<!--Modified on: 11/12/2019 9:05:36 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="omer-20191112.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.omeros.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.omeros.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="omer-20191112.xsd#omer_DocumentAndEntityInformationAbstract" xlink:label="omer_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637091895364280720" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637091895364280720" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637091895364280720" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637091895364280720" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637091895364280720" order="5" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637091895364280720" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637091895364280720" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637091895364280720" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637091895364280720" order="9" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637091895364280720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637091895364280720" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637091895364290708" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637091895364290708" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637091895364290708" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637091895364290708" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637091895364290708" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637091895364290708" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637091895364290708" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637091895364290708" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637091895364290708" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637091895364290708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637091895364290708" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637091895364300700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637091895364300700" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637091895364300700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="omer_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637091895364300700" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>7
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "omer-20191112x8k3397499.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "omer-20191112x8k3397499.htm"
     ]
    },
    "labelLink": {
     "local": [
      "omer-20191112_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "omer-20191112_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "omer-20191112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "omer",
   "nsuri": "http://www.omeros.com/20191112",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "omer-20191112x8k3397499.htm",
      "contextRef": "Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.omeros.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "omer-20191112x8k3397499.htm",
      "contextRef": "Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.omeros.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "omer_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.omeros.com/20191112",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>11
<FILENAME>0001558370-19-010800-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-19-010800-xbrl.zip
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M-)KM1J]5KW<[K>X/1_K7V+\>+?KYS4_OW\%8ZQR0ICZ9'NRP-DF.$O$MJ?#
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ML_Y+33S_2A@830XK+81M)'UDLX?$%/T;<82OK&B3IEZK_4#8T3\]8E/D_P*
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MQ&467C'@[M?K&.W<RO3>N6 $QX>H#1SI].(&@%'QJL.:X2A-PU+,A[S\=]T
M7/^ Z\6OI5#KP0J1E[$"7BY%03'.XZ,SY,A*F948TY%2\^<HC1GHQP'^\O/'
M_B(?*055GFYPW!.6N?K41];-IW@D+!T8.$(?9PK31.47>>L 6/"8$B#8. U
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M9N"^*#;C>_>OK!'?&3;B0U<N]ER]U)WX3",^W)@+%)_$U)6@_!WVZT0)Y<S
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MIHJ@%"(M=YP!57P#TU[Z-]CYP4JF<EJ.ULC?"B-_J1;:AA$J7=$X 54IG0!
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M5B],=7^]_+\LN]FGE<_VZREL+=;\OVUT"Y"AIJURY# %P+]2_P8H-]2<3(X
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M6#H7'82AJ%@4*'N-1X3.K"X1WY**AUY:PK)#=?2JTJ)N;V^K$;&^*DSN^>8
MBCG93A3PS +9IS=H.F6QX_S$C3,RK# 8+?.^Y_B#!MA"QJ;W)6-C+C:U4UI(
MX5&$-?X.O+2]F)<8SLZ1&Q"'P$,%931,;BGI*+H-\6P3W:%6,0=X$<R%QW>6
M/I]1*2F:]0/0"-6ZM$9]',43C>)E6>GF[\$"%8G6005'V<')F&/]W=,X326^
M9[2E2)T'Z9B4O;RGB3G*Q_\O^4NG,^WT"9&)4*D1,9_0FY2!$V"R7465?Q<C
M*( 3(]5+55<VR4+BM*I#1R6O,J8*>9@C3!"9AW3P$]GF69H%VC[H80W!BL$\
M;MT+G$I&,4-#5$PT-!]$^>/H990S(J>*Q! BU&PZ/Q.)7,ZK]/W4$:['/YI_
M13,9G7F5%GQ0+1U 7-"B8(N/\.&*=EVHU#S@W/W3Y;NK%J7!WJ38/Y6 ^#7K
MH>HCH"/8=0XR6+=0W3<]5)]32&65 83D:*/3\;. )5G?0IRIJ1\T;GDPE_"P
MJ85E4D-8!VJ-.LZQ -\TEJGF8B;6P,$Z$,Y4,BK<B]U5A3XC!,,#L9AOHYBC
M7);Y!;8TS$QC/C5-GSDW5(FRR,-V%JBPTOEEQ2PG]!;P;[[4[5R#NXR2BS6:
M57;YG>Q8(B*="X5"=*+5]=D>(7$$HABLR?B._6*HO>+"<C'_S:2HL3T\(WX_
MJS[+4MWTN1])UAZ)M5NT%#I3GDA+P4 ;9G1P/>A%*HW-,SP!G7=R*I]+Y6R9
MGA)HB !Y2)5O9Z!K\HFS'&,LS3#'V)>%[Z\ND4IW+/:<CO!P6 ?T-Z_R,<+V
M?]?*.'O,<:$EWIRR;,=T_R J74(5'42(T<@3:CDVU'L1Z+V0V5Z8! <4N+KI
MLO(5*C.@T>T;<7R)1QF0UX3U54ON>J^I^'-V=_UTP=VGWUS0"8!?YX^US)E!
MR)L*WDM\TA@KD@_QY*AX$,69Q>+J(XRH@QOF F3-U53?''=46!J>@A$4EZKR
M,.@\HN+5(0/( 9LCMCZD)MBQN =DQ;F#D2(R=4=/3&!]+LT%I(A937X,>'ZZ
MN?EM( ),;9G_P<6N//.7L5O2>.%(JHI^_CH>1S)_51UO,7\]\+\"RUUP'4!A
MX *[-7\#&&?S%R/:77_1^C#<ON!JE*@,HP4_H:]]T0+U4>;S/\C18AA23>'\
M926NYJ^C)VO!51P[NTH*A0^$"UH4; 0U!$#4Q.LW//:-/HPN]VA891^^3Y2(
M6@.NU9C<-YH[,@AEAFIL+F4ZGB39NRB;&:6@SD#*G&] 8 4_JSIB+=.VE9=T
M:"H@"VRD.JLU8(9%P>=*6 KZR7 (U(5X&:N*2>V=0S+-L=^<;B#OHS"BYC'J
M 1C!Q:!NKF4YV4%I <!:I>P[+/;EU_ET$]-)K&CIY&E9!2N@$#YF:8C>8Q%.
M:7MT?];<HJ!WYKYD[)5SC0H='D@745]^$)785Q*9'Z413)^F6CP\=A(% "#5
M6[Z0*+;H %<TLM29;X7.9=A<!SF.&<<A?QCUMDV5L@HK!)U2G4NKLB3 *"-3
MLMB\W,'3ZG0K-L<H;0JZ"!G03U&@$%O/,]N09Z+*F9_*E'N61H*3GF=(Y@L,
MQ3ZH!S+*T?)GSEW7#\.4LJRIKP<L\P-JG_5:Y5]LZ ?%I**"N,%Y92*'&I7H
M'ITA]H #&&5G6G%)=1S*1,"J $)8D+$DBO!?W2ET;F*_J6Q'0'(U-UF<W&]5
M]HN/"*30?#G@.>PN2IGB5G0Z%/!&,$L D"FZIP.?ZRJ-AV@GW[5,ET;^ .\,
M(Q8- M,&$ ^:4J&1AT?$)$[F#TFU+[*6@8!WB&(NANE<FN)QAUN@A9=%T;O7
M-W>,:IZ;/*>AOG1G$;N5CP'K/T48^B@VCU&U^@/#_WQ<&OMHE15-+838;QH:
M5Z##SD*W-$QAE=69.$EVZB$' :!:DF[TKC4[M6JG<U!M=FOUYUS'DF4X*Z_C
M3TU/_^/>HMI4C>+KQWE+&R5D+"_+\I;,-5Q9>BV=268S)6VFY#9G2JH\ 2JC
M/W3I9-V2TNOYI],OYY?L^/S+Q?F7_M79^>=M6^'OG_N_GYQ=G9[ (C]?GG\\
M.^GCE\LK^.?3Z>>K2W;^@9U?G*K57V[;\O?.T&J+4@E:#5I[WS#LHXH4E)/"
ME"Q0Q?Y^*?CW(]N:'&5]31[H86*Z7*@-RUJ-Z-(+/"Z(3Z0X-!]T[PS6:U35
M6]34D]@T YGM8S(ULV:KVCQ ]DW3.:Q5#Y"SJK\UCS7Q7VIQ8EJ,/ W>4T,>
MH;-I&$2WAR/?\T18V(UB4Y.EU91Y+<5LC.Y+,@\75: T YI:H]H @$[/-0-4
M<68[  N87L?"0A%SH]JK69*Q)/,@R=0M+"S)6))Y#,ET6A86AF0Z'4LR"]&D
M6>TT+)I8*3-+,O5JVY+,8C2I55N[H;]3X[IUF\#W0B?KEMVM-HS+Q0]AP<DA
MJZAK3\^D7!YBZ]1*EL>0M>:*+H\3CR$0F**<<%AQ^\W]BV_6JG5 B&4ZFY W
M>)F^)S(*?(]I^&0W*'?Q_//+PWW>P??DG3AXW$8LDX^KAKP:Q4*HO?H$/XUT
MSOTIT(KW?A#_E%6'J^O-FF-Q^ DXW*E9'%X[#G^&9UX0A978?DD47JN@>4@8
MCT$Q",2:Y?&+ N'^%HN6;\WRK<8#?*O>K/8Z<WQK,><I(>,J$ZO"1-%U(.)Z
M]V+A[T_?BJVB@5:UUK TL"8:.+#,^ F(V%P[ ]A91'PB,U9.3\N,7YH&E!_>
MTD 9F/&6FT/?]4W.Y4VROQ\?GYY^^+"4LQLXQT/>[A?Q82Y/U _4=7]1+=T/
MUZ+=?A>TT^![=JS+O.7L">[R!P#'%(JJO]DZ,H)>41YMU\ZM,\^BE)NR)DZU
M\7NTE7QG12ULF=!V*9%Y$_?(<AC+8387>Y^)PV"^62F1>1/W:)V);Z7<%,MA
MIIU16X6]5H<I_QZM,T^PE)MB.<R4JV^[L/?1R0*OF,S8J%5[Y?<$7NCV6G02
MJ8-G;=EHWPI>O'(N^*$#6-=AR#YU/7F[?15V(8Y_] ;X_6W,)S^^4?].=T$
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M%F+.$OK)4]-YYE7B)[M]#E: XL&:F7")O5Q%5?^!W!^F *+^9@_!!08#31H
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MVPU&41E%PI=K-!0W=8W' K9R V&W"=2-O1ZYRX_$EWRS4UGON_\!4$L#!!0
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M?7)7(G$Z:EZ-%'K6S^\@&P_X^,3,E6R8R+0 $V78*ML&F9R2Z0XRC>\[QP*
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MY84<T[ZVRDBGJ .@@C@R'63RK'D#\.U2Y)@#SW*Q3:CG6%/DP-)T.E/1/&A
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M A!EV^#>'4'M*=+%I@(4]T';$9%'^R#8;SH(0 ;7D/?015U&QVZ/.XE#O@&
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MW>4'_P]02P$"% ,4    " "]@&Q/<%KX?),P   !4 ( "P
M@ $     97@M.3ED,2YH=&U02P$"% ,4    " "]@&Q/Q/?W1ZX#  #/#
M$0              @ &\,   ;VUE<BTR,#$Y,3$Q,BYX<V102P$"% ,4
M" "]@&Q/CET)'HH%  #9/   %0              @ &9-   ;VUE<BTR,#$Y
M,3$Q,E]L86(N>&UL4$L! A0#%     @ O8!L3T?F\T>0!   62D  !4
M         ( !5CH  &]M97(M,C Q.3$Q,3)?<')E+GAM;%!+ 0(4 Q0    (
M +V ;$^C>W5N?A,  *F    ;              "  1D_  !O;65R+3(P,3DQ
G,3$R>#AK,S,Y-S0Y.2YH=&U02P4&      4 !0!' 0  T%(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>omer-20191112x8k3397499_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="omer-20191112.xsd" xlink:type="simple"/>
    <context id="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001285819</identifier>
        </entity>
        <period>
            <startDate>2019-11-12</startDate>
            <endDate>2019-11-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Hidden_Wa_jfEWeEU24VPQtU1k4Dw">0001285819</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Hidden_wKz9Oslh906kWDCXegOtow">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr__vxu1RrgO0K0z0LF1Y9xQA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_djnq3ODF5US4OaPFD-K3KA">2019-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_huuTwTDauEy81T9CGGqszA">OMEROS CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Tc_9cACTKAuF0S4LkpJ7ycMnw_0_0">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Tc_1bftqEFa10-WJ5spGHfOOg_0_1">001-34475</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Tc_XsvEozzFyU2H3zG6uCZ4xA_0_2">91-1663741</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_YkGsLX_Dqki7KTv1hJd-xA">201 Elliott Avenue West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_HeUgZojYnUuLqGNxuncoGw">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_zA4JWxdjN0u3fcMkuhSgNw">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Tc_HfN4s6XJCk62gYkRmQrGmg_3_2">98119</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_6Z7uulVm906IIzFfRi_gng">206</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_qniYHwWuOkKcKwj-_6dHGA">676-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_7Bhx_O2rAkaLYWVyNgcYGg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_soFLsgWsRkSc49NqJjYwvw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_6J_0O4d8ZUCp_OoqlDuqUg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_Fnxx0O94QECoWVCASNdKKA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Tc_PagvLSZpyU-jYkDUk10Wmw_1_0">Common stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Tc_1LeJB3Ase02AgB0S7X1QoQ_1_1">OMER</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Tc_Lk7_6Kb8b0yu1ltm_oQE2w_1_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_12_2019_To_11_12_2019_85Jy6-XJqEe3ovUWv0oLkA"
      id="Narr_h48fTZC4wEGclUnXUCes0w">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="omer-20191112x8k3397499.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.omeros.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="omer-20191112x8k3397499.htm">omer-20191112x8k3397499.htm</File>
    <File>ex-99d1.htm</File>
    <File>omer-20191112.xsd</File>
    <File>omer-20191112_lab.xml</File>
    <File>omer-20191112_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^-V$7C-W;?VQ\%90-_+H+^0502P,$%     @ O8!L3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " "]@&Q/[8\]^*("  "8"P  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'56[8Z;,!!\%<0#'-B03R5(S555*[52=%6OOYW$">@ 4]L)
MU[>O;3B*O.L_8)N9'9MEEMWU0KZIDG,=O3=UJ_9QJ76W31)U+GG#U)/H>&N>
M7(5LF#93>4M4)SF[.%)3)S1-ETG#JC8N=F[M*(N=N.NZ:OE11NK>-$S^/?!:
M]/N8Q!\++]6MU'8A*78=N_&?7/_JCM+,DBG*I6IXJRK11I)?]_$GLCW0W!(<
MXK7BO9J-(WN4DQ!O=O+MLH]3NR->\[.V(9BY/?@SKVL;R>SCSQ@TGC0M<3[^
MB/[%'=X<YL04?Q;U[^JBRWV\CJ,+O[)[K5]$_Y6/!UK$T7CZ[_S!:P.W.S$:
M9U$K=XW.=Z5%,T8Q6VG8^W"O6G?OAR=Y/M)P AT)]#_!Z22#D-OY9Z99L9.B
MC^3P\CMF<TRVU+R;LUUTK\(],YM79O51I+OD8<.,B,. H#,$F1")B3T)4%2
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M6>U,*90C*>06I8<VW>=B\^_6XU_ Z#=02P,$%     @ O8!L3[JA.8K7 0
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M     %]R96QS+RYR96QS4$L! A0#%     @ O8!L3R?HAPZ"    L0   !
M             ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "]
M@&Q/N-(#?N\    K @  $0              @ &9 0  9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "]@&Q/F5R<(Q &  "<)P  $P
M@ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +V ;$_MCSWX
MH@(  )@+   8              "  ?@(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "]@&Q/?AV>?%("   (!@  %
M@ '0"P  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "]@&Q/NJ$Y
MBM<!   R!@  #0              @ %4#@  >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( +V ;$\6;2-_0P$  #P"   /              "  580  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "]@&Q/_\ F"+T   "% @  &@
M        @ '&$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "]@&Q/"X_8 R$!  !7!   $P              @ &[$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "@ * ( "   -%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6621392432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_omer_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OMEROS CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001285819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1663741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">201 Elliott Avenue West<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">676-5000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_omer_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">omer_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>omer_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
